This study is currently not recruiting participants.

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Observational research study of Atopic Dermatitis in Children

Not Recruiting
11 years or below
All
Phase N/A
1860 participants needed

Study Overview

Primary Objectives:

  • To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
  • To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

  • To characterize disease burden and unmet need.
  • To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
  • To document the real-world effectiveness and safety of treatments.

Study Details

The study duration is 120 months.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dermatitis Atopic
  • Age: 11 years or below
  • Gender: All

Inclusion criteria:

  • Patients with moderate to severe AD, according to the Investigator's assessment;
  • Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion criteria:

  • Concurrent participation in an interventional clinical trial which modifies patient care.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

This study investigates atopic dermatitis in pediatric patients. It focuses on children with moderate to severe conditions not controlled by topical treatments.

The purpose of this study is to observe the characteristics and progression of atopic dermatitis and related conditions. It also evaluates the burden of the disease and treatment patterns in real-world settings.

  • Who can participate: Children with moderate to severe atopic dermatitis who are receiving systemic treatment or are candidates for it can participate.
  • Study details: Participants will be observed to understand their treatment patterns and the effectiveness and safety of their current treatments. The study will also document reasons for treatment changes.
  • Study timelines: The study will last 120 months.
Updated on 23 May 2026. Study ID: NCT03687359